Discovery of Potential Anti-tuberculosis Agents
Tuberculosis(TB), driven primarily by Mycobacterium tuberculosis, continues to pose a severe global health challenge, especially with the rise of multidrug-resistant (MDR) strains. Current treatments are insufficient, creating an urgent demand for new therapeutic options. In our study, we introduce compound X that demonstrates potent efficacy against both actively replicating and dormant M. tuberculosis, including MDR strains. In animal models, compound X exhibits strong in vivo activity, effectively combating both acute and chronic MDR infections. These results highlight compound X as a compelling candidate for advancing the treatment of MDR-TB.
Short bio
Dr. Jichan Jang is a Professor in the Division of Life Science at Gyeongsang National University, Korea. He earned his PhD from Aix-Marseille II Université, France, in 2007, specializing in signal transduction in Anabaena sp. PCC7120. Following his doctoral studies, Dr. Jang completed a Postdoctoral Fellowship at the Unité de Génétique Mycobactérienne at Institut Pasteur in Paris, co-supervised by Prof. Brigitte Gicquel and Dr. Olivier Neyrolles. From 2008 to 2015, he worked as a Scientist and Group Leader in the tuberculosis (TB) research laboratory at Institut Pasteur Korea, contributing to the development and biological understanding of the novel anti-TB drug Q203, which completed clinical phase IIa. His current research focuses on identifying and characterizing novel genes in nontuberculous mycobacteria (NTM), discovering new drugs for TB and NTM diseases using compound libraries, and utilizing cell-based and zebrafish in vivo models to mimic human TB and NTM diseases for drug screening and therapeutic development.
Laboratory of the speaker
Division of Life Science, Gyeongsang National University, Republic of Korea
Invited by
